Artwork

Conteúdo fornecido por Surescripts. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Surescripts ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !

Innovation, Please: What's Next and What's Needed in Specialty Therapy

33:48
 
Compartilhar
 

Manage episode 340276689 series 3377975
Conteúdo fornecido por Surescripts. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Surescripts ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

As the U.S. population ages, it’s also getting sicker: According to the CDC, more than a quarter of U.S. adults face multiple chronic conditions. An ever-increasing number of Americans are on a specialty therapy or medication—more than 66 million in 2022. The good news? Conditions that were untreatable decades ago now have effective therapies. The bad news? The journey from diagnosis to treatment remains costly and onerous: CVS reported that specialty medications accounted for more than 52% of drug spend in 2020. In addition, underserved and minority populations often don’t get the specialty medication access and education they need to improve their outcomes. Melanie will chat with Joel Helle on what's needed and what's next with specialty prescribing & dispensing—and how technology and innovation play important roles. We’ll ask Joel to share his professional and personal experience with improving the specialty journey—and why he’s passionate about making this process better for the pharmacist, for the patient, for the doctor. We’ll also talk about what inspires Joel—and what he thinks the future holds for a market ripe for innovation.

  continue reading

22 episódios

Artwork
iconCompartilhar
 
Manage episode 340276689 series 3377975
Conteúdo fornecido por Surescripts. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Surescripts ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

As the U.S. population ages, it’s also getting sicker: According to the CDC, more than a quarter of U.S. adults face multiple chronic conditions. An ever-increasing number of Americans are on a specialty therapy or medication—more than 66 million in 2022. The good news? Conditions that were untreatable decades ago now have effective therapies. The bad news? The journey from diagnosis to treatment remains costly and onerous: CVS reported that specialty medications accounted for more than 52% of drug spend in 2020. In addition, underserved and minority populations often don’t get the specialty medication access and education they need to improve their outcomes. Melanie will chat with Joel Helle on what's needed and what's next with specialty prescribing & dispensing—and how technology and innovation play important roles. We’ll ask Joel to share his professional and personal experience with improving the specialty journey—and why he’s passionate about making this process better for the pharmacist, for the patient, for the doctor. We’ll also talk about what inspires Joel—and what he thinks the future holds for a market ripe for innovation.

  continue reading

22 episódios

Todos os episódios

×
 
Loading …

Bem vindo ao Player FM!

O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.

 

Guia rápido de referências